USD 12.9 billion
Report ID:
SQMIG35A2611 |
Region:
Global |
Published Date: February, 2025
Pages:
157
|Tables:
100
|Figures:
69
Intravenous Immunoglobulin Market size was valued at USD 12.9 billion in 2023 and is poised to grow from USD 13.84 billion in 2024 to USD 24.32 billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032).
The market for intravenous immunoglobulin (IVIG) is propelled by several key drivers, including the burgeoning geriatric population, a surge in immunodeficiency diseases, wider adoption of IVIG treatments, and the expanding use of off-label indications. The escalating prevalence of patients grappling with immunodeficiency disorders remains a primary catalyst behind the development and demand for IVIG preparations.
This global market is experiencing rapid expansion, attributed to a growing number of patients contending with bleeding issues and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The increased investments in the healthcare sector further support the growth of the IVIG market.
Moreover, the mounting incidence of autoimmune illnesses and various pathological conditions contributes significantly to the expanding market landscape for IVIG products, underscoring their pivotal role in addressing diverse medical needs.
Market snapshot - 2025-2032
Global Market Size
USD 12.9 billion
Largest Segment
Specialty Pharmacy
Fastest Growth
Specialty Pharmacy
Growth Rate
7.3% CAGR
To get more reports on the above market click here to Buy The Report
Global Intravenous Immunoglobulin Market is segmented by Product, Distribution Channel, Application and region. Based on Product, the market is segmented into IGG, IGA, IGM, IGE and IGD. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Specialty Pharmacies and Other. Based on Application, the market is segmented into Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal motor neuropathy, ITP, Kawasaki disease, Guillain-Barre syndrome and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
In 2022, immunodeficiency diseases emerged as a dominant force in the market, commanding a substantial revenue share exceeding 20.30%. This dominance is attributable to the escalating incidence of both primary and acquired immunodeficiency diseases (PID & AID). Treating PID & AID often requires IV antibiotics to combat infections, with IVIG replacement therapy standing out as the premier alternative for managing these conditions. Consequently, the sector is poised for steady growth in the foreseeable future.
The chronic inflammatory demyelinating polyneuropathy (CIDP) segment secured the second-largest share in the IVIG market based on its application. Commonly identified in patients with diabetes mellitus, CIDP treatment typically involves the utilization of immunosuppressive drugs, steroids, and plasmapheresis. IVIG stands out as a highly effective and enduring alternative to these conventional methods. Its adoption is bolstered by associated benefits such as safety, minimally invasive administration, and user-friendly treatment options.
The forecast period anticipates significant growth within the specialty pharmacy segment, primarily due to the inherent advantages they offer in facilitating convenient home-based treatments. Specialty pharmacies play a pivotal role in this trajectory, providing ease of access and administration for specialized medications at patients' homes. As the landscape of pharmacy business evolves, specialty drugs have emerged as a crucial and dynamic sector.
In 2022, the hospital pharmacy segment established its dominance within the market, securing a substantial revenue share exceeding 57.83%. This prevalence stems from the widespread reach of hospitals housing these pharmacies, providing convenient access to a diverse array of pharmaceutical products. Moreover, the global upsurge in hospitalizations due to conditions like primary immune deficiencies, hepatitis C, and several other diseases has notably influenced consumer behavior.
To get detailed analysis on other segments, Request For Free Sample Report
In 2022, North America emerged as the leading force within the market, securing a commanding revenue share of 46.51%. The region's dominance stems from several pivotal factors fostering its market growth. Notably, there has been a substantial uptick in awareness regarding products designed to address immunodeficiency diseases, fostering a deeper understanding among both healthcare professionals and the general populace.
Asia Pacific is positioned for remarkable growth, propelled by a convergence of key factors. Heightened awareness and increasing opportunities surrounding the adoption of immunoglobulin-based therapies for addressing primary immune deficiencies serve as primary catalysts for this growth. The expanding geriatric demographic within the region also emerges as a pivotal factor contributing to this upward trajectory, amplifying the demand for specialized therapies. Moreover, the region's emerging economies, coupled with increasing healthcare expenditures, further bolster the sector's development.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Adoption of Intravenous Immunoglobulins to Drive Market Growth
High Cost of Treatment to Impede Market Growth
Request Free Customization of this report to help us to meet your business objectives.
The competitive environment of the global Intravenous Immunoglobulin Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry.
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
The global Intravenous Immunoglobulin market analysis reveals a dynamic marketplace with a number of standout trends and difficulties. The market for Intravenous Immunoglobulin (IVIG) is principally steered by several key factors. Among these are the expanding elderly population demographic, the rising incidence of immunodeficiency disorders, increased adoption of IVIG treatments, and the growing utilization of off-label indications. IVIG preparations have notably evolved in response to the escalating number of patients afflicted by immunodeficiency disorders. This surge in demand and the expanding spectrum of applications for IVIG underscore its critical role in addressing various medical conditions and the growing need for therapeutic solutions in diverse patient populations.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 12.9 billion |
Market size value in 2032 | USD 24.32 billion |
Growth Rate | 7.3% |
Base year | 2024 |
Forecast period | 2025-2032 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Intravenous Immunoglobulin Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Intravenous Immunoglobulin Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Intravenous Immunoglobulin Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Intravenous Immunoglobulin Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Intravenous Immunoglobulin Market size was valued at USD 12.9 Billion in 2023 and is poised to grow from USD 13.84 Billion in 2024 to USD 24.25 Billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032).
The competitive environment of the global Intravenous Immunoglobulin Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry. 'Grifols SA', 'Octapharma AG', 'ADMA Biologics', 'LFB Biotechnologies', 'Kedrion Biopharma', 'Intas Pharmaceuticals', 'Biotest AG', 'BDI Pharma Inc.', 'Shanghai RAAS Blood Products Co., Ltd.', 'Takeda Pharmaceutical Company Limited.', 'CSL Behring', 'Baxter International Inc.', 'China Biologics Products Inc.'
The pervasive uptake of intravenous immunoglobulin therapy as the foremost treatment avenue for numerous rare immunological and neurological conditions, notably primary immunodeficiency (PI) and associated diseases, emerges as a cornerstone propelling the expansion of the intravenous immunoglobulin market. This extensive acceptance of IVIG therapy as the frontline treatment signifies its efficacy and relevance in managing these conditions effectively.
The market's evolution is being driven by several impactful trends that are reshaping its trajectory for growth and progress. Notably, the rising use of Intravenous Immunoglobulin (IVIG) in treating neurological disorders marks a significant trend, highlighting its expanding application beyond traditional uses. Additionally, the integration of personalized medicine principles into IVIG therapy represents a notable shift, tailoring treatments to individual patient needs. The emergence of novel immunomodulatory treatments is also shaping the landscape, offering innovative therapeutic avenues.
In 2022, North America emerged as the leading force within the market, securing a commanding revenue share of 46.51%. The region's dominance stems from several pivotal factors fostering its market growth. Notably, there has been a substantial uptick in awareness regarding products designed to address immunodeficiency diseases, fostering a deeper understanding among both healthcare professionals and the general populace.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35A2611
[email protected]
USA +1 351-333-4748